(Q51819781)

13 April 2018

title

Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. (English)

1 reference

13 April 2018

0 references

R A Adler

1

1 reference

13 April 2018

F W Hastings

series ordinal

2

1 reference

13 April 2018

V I Petkov

series ordinal

3

1 reference

13 April 2018

language of work or name

English

0 references

publication date

17 June 2009

1 reference

13 April 2018

Osteoporosis International

published in

1 reference

13 April 2018

volume

21

1 reference

13 April 2018

issue

4

1 reference

13 April 2018

page(s)

647-653

1 reference

13 April 2018

https://scigraph.springernature.com/pub.10.1007/s00198-009-0984-0

exact match

0 references

cites work

Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0984-0

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0984-0

The need for increasing awareness of osteoporosis in men.

21 January 2018

1 reference

12 December 2020

Association of Testosterone and Estradiol Deficiency with Osteoporosis and Rapid Bone Loss in Older Men

1 reference

12 December 2020

Racial differences in the prevalence of vertebral fractures in older men: the Baltimore Men's Osteoporosis Study

1 reference

12 December 2020

Approach to the prostate cancer patient with bone disease

1 reference

12 December 2020

Osteoporosis after orchiectomy for prostate cancer

1 reference

12 December 2020

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

1 reference

12 December 2020

Screening for osteoporosis in men: comment on the American College of Physicians clinical guidelines

1 reference

12 December 2020

Alendronate for the Treatment of Osteoporosis in Men

1 reference

12 December 2020

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

12 December 2020

Body mass index as a predictor of fracture risk: a meta-analysis.

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

1 reference

12 December 2020

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

1 reference

12 December 2020

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

12 December 2020

Fracture risk in patients with prostate cancer on androgen deprivation therapy

1 reference

12 December 2020

Survival following primary androgen deprivation therapy among men with localized prostate cancer

1 reference

12 December 2020

Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application

1 reference

12 December 2020

Risk of fracture after androgen deprivation for prostate cancer

1 reference

12 December 2020

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

1 reference

12 December 2020

Cost-effective osteoporosis treatment thresholds: the United States perspective

1 reference

12 December 2020

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

1 reference

12 December 2020

10.1007/S00198-009-0984-0

Identifiers

DOI

1 reference

13 April 2018

1 reference

13 April 2018